metagenomic next-generation sequencing

The DigiSep trial assessed the impact of metagenomic next-generation sequencing (mNGS) on sepsis outcomes. While primary endpoint improvement was not significant, secondary analyses revealed benefits in mechanical ventilation duration, shock resolution, and quality of life without raising healthcare costs.